Cargando…

Fatigue in myasthenia gravis: risk factors and impact on quality of life

OBJECTIVES: Emerging evidence suggests that fatigue in myasthenia gravis (MG) is a relevant problem that negatively impacts activities of daily living (ADL). The relationship between fatigue and quality of life (QoL) has never been systematically explored in MG patients. The study aimed to assess th...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoffmann, Sarah, Ramm, Johanna, Grittner, Ulrike, Kohler, Siegfried, Siedler, Jana, Meisel, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5064345/
https://www.ncbi.nlm.nih.gov/pubmed/27781147
http://dx.doi.org/10.1002/brb3.538
_version_ 1782460140640796672
author Hoffmann, Sarah
Ramm, Johanna
Grittner, Ulrike
Kohler, Siegfried
Siedler, Jana
Meisel, Andreas
author_facet Hoffmann, Sarah
Ramm, Johanna
Grittner, Ulrike
Kohler, Siegfried
Siedler, Jana
Meisel, Andreas
author_sort Hoffmann, Sarah
collection PubMed
description OBJECTIVES: Emerging evidence suggests that fatigue in myasthenia gravis (MG) is a relevant problem that negatively impacts activities of daily living (ADL). The relationship between fatigue and quality of life (QoL) has never been systematically explored in MG patients. The study aimed to assess the prevalence of fatigue and its relation to ADL and QoL as well as to identify factors associated with fatigue in MG. MATERIAL AND METHODS: This was a cross‐sectional observational study in patients with confirmed diagnosis of MG independent of disease severity. Prevalence of fatigue was assessed using the Chalder Fatigue Scale (CFQ). Impact of fatigue on ADL and QoL was assessed by the MG activities of daily living profile (MG‐ADL) and the MG‐specific quality‐of‐life instrument (MG‐QoL), respectively. Association of fatigue with sociodemographics, clinical characteristics of MG, and comorbidities including mood and anxiety disorders as well as sleep disorders was investigated using multivariable logistic regression analyses. RESULTS: Overall, 200 MG patients were included. The observed rate of fatigue was 56.1%, of those 70.4% fulfilled the criteria of chronic fatigue (CF) with a duration of ≥6 months. Relevant fatigue was strongly associated to ADL and QoL. Factors associated with relevant fatigue were disease severity and depressive state. Furthermore, positive muscle‐specific tyrosine kinase (MuSK) antibody status showed a strong association with relevant fatigue. CONCLUSIONS: MG patients have a high prevalence of fatigue which negatively impacts ADL and QoL. MG‐specific clinical characteristics are related to fatigue and might help to identify MG patients at risk for fatigue.
format Online
Article
Text
id pubmed-5064345
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-50643452016-10-25 Fatigue in myasthenia gravis: risk factors and impact on quality of life Hoffmann, Sarah Ramm, Johanna Grittner, Ulrike Kohler, Siegfried Siedler, Jana Meisel, Andreas Brain Behav Original Research OBJECTIVES: Emerging evidence suggests that fatigue in myasthenia gravis (MG) is a relevant problem that negatively impacts activities of daily living (ADL). The relationship between fatigue and quality of life (QoL) has never been systematically explored in MG patients. The study aimed to assess the prevalence of fatigue and its relation to ADL and QoL as well as to identify factors associated with fatigue in MG. MATERIAL AND METHODS: This was a cross‐sectional observational study in patients with confirmed diagnosis of MG independent of disease severity. Prevalence of fatigue was assessed using the Chalder Fatigue Scale (CFQ). Impact of fatigue on ADL and QoL was assessed by the MG activities of daily living profile (MG‐ADL) and the MG‐specific quality‐of‐life instrument (MG‐QoL), respectively. Association of fatigue with sociodemographics, clinical characteristics of MG, and comorbidities including mood and anxiety disorders as well as sleep disorders was investigated using multivariable logistic regression analyses. RESULTS: Overall, 200 MG patients were included. The observed rate of fatigue was 56.1%, of those 70.4% fulfilled the criteria of chronic fatigue (CF) with a duration of ≥6 months. Relevant fatigue was strongly associated to ADL and QoL. Factors associated with relevant fatigue were disease severity and depressive state. Furthermore, positive muscle‐specific tyrosine kinase (MuSK) antibody status showed a strong association with relevant fatigue. CONCLUSIONS: MG patients have a high prevalence of fatigue which negatively impacts ADL and QoL. MG‐specific clinical characteristics are related to fatigue and might help to identify MG patients at risk for fatigue. John Wiley and Sons Inc. 2016-08-02 /pmc/articles/PMC5064345/ /pubmed/27781147 http://dx.doi.org/10.1002/brb3.538 Text en © 2016 The Authors. Brain and Behavior published by Wiley Periodicals, Inc. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research
Hoffmann, Sarah
Ramm, Johanna
Grittner, Ulrike
Kohler, Siegfried
Siedler, Jana
Meisel, Andreas
Fatigue in myasthenia gravis: risk factors and impact on quality of life
title Fatigue in myasthenia gravis: risk factors and impact on quality of life
title_full Fatigue in myasthenia gravis: risk factors and impact on quality of life
title_fullStr Fatigue in myasthenia gravis: risk factors and impact on quality of life
title_full_unstemmed Fatigue in myasthenia gravis: risk factors and impact on quality of life
title_short Fatigue in myasthenia gravis: risk factors and impact on quality of life
title_sort fatigue in myasthenia gravis: risk factors and impact on quality of life
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5064345/
https://www.ncbi.nlm.nih.gov/pubmed/27781147
http://dx.doi.org/10.1002/brb3.538
work_keys_str_mv AT hoffmannsarah fatigueinmyastheniagravisriskfactorsandimpactonqualityoflife
AT rammjohanna fatigueinmyastheniagravisriskfactorsandimpactonqualityoflife
AT grittnerulrike fatigueinmyastheniagravisriskfactorsandimpactonqualityoflife
AT kohlersiegfried fatigueinmyastheniagravisriskfactorsandimpactonqualityoflife
AT siedlerjana fatigueinmyastheniagravisriskfactorsandimpactonqualityoflife
AT meiselandreas fatigueinmyastheniagravisriskfactorsandimpactonqualityoflife